Brokerages predict that Surface Oncology, Inc. (NASDAQ:SURF) will post earnings of ($0.36) per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Surface Oncology’s earnings, with the lowest EPS estimate coming in at ($0.44) and the highest estimate coming in at ($0.20). Surface Oncology posted earnings of ($0.39) per share during the same quarter last year, which suggests a positive year over year growth rate of 7.7%. The firm is scheduled to announce its next quarterly earnings report on Tuesday, November 9th.
According to Zacks, analysts expect that Surface Oncology will report full-year earnings of ($1.24) per share for the current financial year, with EPS estimates ranging from ($1.73) to ($0.96). For the next fiscal year, analysts anticipate that the business will report earnings of ($1.55) per share, with EPS estimates ranging from ($1.67) to ($1.44). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Surface Oncology.
Surface Oncology (NASDAQ:SURF) last announced its quarterly earnings data on Thursday, August 5th. The company reported ($0.44) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.13). The company had revenue of $0.52 million during the quarter.
Several institutional investors and hedge funds have recently modified their holdings of the company. Bank of New York Mellon Corp lifted its holdings in shares of Surface Oncology by 1.9% during the 1st quarter. Bank of New York Mellon Corp now owns 77,029 shares of the company’s stock valued at $601,000 after purchasing an additional 1,401 shares during the last quarter. BNP Paribas Arbitrage SA purchased a new stake in shares of Surface Oncology during the 2nd quarter valued at $26,000. UBS Group AG lifted its holdings in shares of Surface Oncology by 52.9% during the 1st quarter. UBS Group AG now owns 11,466 shares of the company’s stock valued at $90,000 after purchasing an additional 3,966 shares during the last quarter. Captrust Financial Advisors lifted its holdings in shares of Surface Oncology by 4,700.0% during the 1st quarter. Captrust Financial Advisors now owns 4,800 shares of the company’s stock valued at $37,000 after purchasing an additional 4,700 shares during the last quarter. Finally, Oppenheimer & Co. Inc. lifted its holdings in shares of Surface Oncology by 16.3% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 34,834 shares of the company’s stock valued at $260,000 after purchasing an additional 4,870 shares during the last quarter. Hedge funds and other institutional investors own 49.77% of the company’s stock.
Shares of SURF stock traded up $0.17 during trading hours on Wednesday, reaching $7.57. The company’s stock had a trading volume of 3,386 shares, compared to its average volume of 1,318,957. The stock has a market capitalization of $344.07 million, a P/E ratio of 20.56 and a beta of 1.83. Surface Oncology has a one year low of $4.95 and a one year high of $14.40. The firm’s fifty day simple moving average is $6.19 and its 200 day simple moving average is $7.22. The company has a current ratio of 9.13, a quick ratio of 9.13 and a debt-to-equity ratio of 0.07.
About Surface Oncology
Surface Oncology, Inc operates as a clinical-stage immuno-oncology company. It focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The firm’s pipeline includes two wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388); a clinical-stage collaboration with Novartis targeting CD73 (NZV930); and two preclinical programs, each focused primarily on activating natural killer or depleting regulatory T cells.
Featured Article: How is a management fee different from a performance fee?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Surface Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surface Oncology and related companies with MarketBeat.com's FREE daily email newsletter.